{"DataElement":{"publicId":"4379851","version":"1","preferredName":"Contraception Agree Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator that asks whether patients receiving therapy or interventions have agreed to prevent pregnancy until the end of therapy or interventions.","longName":"CONTCPT_AGR_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2014053","version":"1","preferredName":"Contraception Agreement","preferredDefinition":"the patient's agreement to use effective contraception during protocol treatment.","longName":"CONTRACEPTION_AGR","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2725194","version":"1","preferredName":"Contraception","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"C37932","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"448E87D9-8E4A-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-25","modifiedBy":"ONEDATA","dateModified":"2008-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2520617","version":"1","preferredName":"Agreement","preferredDefinition":"1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)","longName":"C25369","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agreement","conceptCode":"C25369","definition":"The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DFE6E80-0641-12A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-21","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-09-21","modifiedBy":"ONEDATA","dateModified":"2006-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B318870A-C908-3702-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876423","version":"1","longName":"Consents & Contraceptive Guidelines","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"CONTCPT_AGR_COD_IND","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Does male patient of fatherin","type":"Preferred Question Text","description":"Does male patient of fathering potential, agree to use a condom if partner is pregnant or breastfeeding?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does male patient (including those who are vasectomized) whose partners are pregnant or might be pregnant agree to use condoms for the duration of the study and for 90 days following completion of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is woman of childbearing potential or man who is sexually active with a woman of child bearing potential, does patient agree to adhere to adequate contraception for 23 weeks for women and 31 weeks for men after the last dose of investigational drug Nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is woman of childbearing potential or man who is sexually active with a woman of child bearing potential, does patient agree to adhere to adequate contraception for 23 weeks after the last dose of investigational drug Nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If male patient has a female partner of childbearing potential, has patient had prior vasectomy or agree to use effective contraception?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does male patient (including those who are vasectomized) whose partners are pregnant or might be pregnant agree to use condoms for the duration of the study and for 6 months following completion of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of AMG 232 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does male patient and their partners who are sexually active, and of childbearing potential, agree to use two highly effective forms of contraception in combination, throughout the period of study treatment and for 3 months after the last dose of study drug(s) to prevent pregnancy in a partner?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does male patient with female partners of childbearing potential or pregnant female partners, agree to remain abstinent or use a condom during the treatment period and for at least 4 months after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Is male patient willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for 3 months after treatment stops?\r\n","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Is male patient willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for 3 months after treatment stops?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Is male patient with female partner of childbearing potential, willing to use barrier contraception during the study and for 6 months following discontinuation of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does male patient agree to use adequate barrier contraception prior to the study, for the duration of study participation, and for 90 days after completion of pinometostat administration?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does male patient agree to use an additional barrier method of contraception for 30 days following the last dose of birinapant?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does male patient agree to use a condom during treatment and for 3 months after the last dose of Olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of KRT-232 (AMG 232) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does male patient, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of GSK525762C administration?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does male patient whose partner is or can become pregnant agree to continue to use condoms for 16 weeks after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does patient commit to abstain from heterosexual intercourse or agrees to begin using two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days prior to day 1 of lenalidomide?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does male patient (even if surgically sterilized) agree to the following contraceptive guidelines: agree to practice highly effective barrier contraception during the entire study treatment and 120 days after the last dose of study drug or agree to practice abstinence.","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does male patient agree to use a condom during treatment and for 3 months after the last dose of study drug when having sexual intercourse with a pregnant woman or with a woman of childbearing potential (female partners of male patient should also use a highly effective form of contraception)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of pembrolizumab (MK-3475) and/or rhIL-12 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does male patient agree to use a latex condom during sexual contact with a female of child bearing potential even if they have had a vasectomy?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If the partner of a male patient is pregnant, does patient agree to use a barrier method contraception (condom) during the study and for 4 months after the last dose of study treatment to prevent fetal exposure to study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized (i.e., status post vasectomy), agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), or agrees to practice true abstinence?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does male patient of reproductive potential agree to avoid impregnating a partner while receiving study drug and for 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has male patient receiving cabozantinib and is sexually active with WOCBP been instructed to adhere to contraception for a period of 5 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Has male patient agree to avoid fathering a child for 4 months after the last dose of Lutetium Lu 177 Dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does male patient taking lenalidomide agree to abstain from donating blood, semen, or sperm during study participation and for at least 4 weeks after discontinuation from lenalidomide?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6C89-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-01","changeDescription":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}